Rituximab in the treatment of non-Hodgkin's lymphoma – a critical evaluation of randomized controlled trials

Bibliography

• Hoffbrand A, Catovsky D, Tuddenham E, Postgraduate haematology. 6th edition. ©Wiley-Blackell, UK; 2011
   Google Scholar
• Grillo-Lopez AJ, White C, Dallaire B, Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000;1:1-9
   PubMedGoogle Scholar
• Teeling J, Mackus J, Wiegman L, The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177(1):362-71
   PubMed Web of Science ®Google Scholar
• Weiner G. Rituximab: mechanism of action. Semin Hematol 2010;47(2):115-23
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Zoppoli G, Massucco C, Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol 2011;186(10):6044-55
   PubMed Web of Science ®Google Scholar
• Straus DJ, Huang J, Testa MA, Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142–low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998;16(11):3601-6
   PubMed Web of Science ®Google Scholar
• Lim ST, Karim R, Tulpule A, Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. Clin Oncol 2005;23(33):8477-82
   Web of Science ®Google Scholar
• Weiss R, Mitrou P, Arasteh K, Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival–results of the German multicenter trial. Cancer 2006;106(7):1560-8
   PubMed Web of Science ®Google Scholar
• Lim ST, Karim R, Tulpule A, Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. Clin Oncol 2005;23(33):8477-82
   Web of Science ®Google Scholar
• Carson K, Evens A, Richey E, Progressive multifocal leukoencephalopathy after rituximab in HIV negative patients: a report of 57 cases from the Research on adverse drug events and reports project. Blood 2009;113(20):4834-40
   PubMed Web of Science ®Google Scholar
• Berger JR. The basis for modelling progressive multifocal leukoencephalopathy pathogenesis. Curr Opin Neurol 2011;24(3):262-7
   PubMed Web of Science ®Google Scholar
• Available from: http://www.cancerresearchuk.org/
   Google Scholar
• Morton LM, Turner JJ, Cerhan JR, Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110(2):695-708
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trumper L, CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12(11):1013-22
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116(12):2040-5
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Six versus eight cycles of Bi-weekly CHOP 14 with or without rituximab in elderly patients with aggressive CD20+ B-Cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9(2):105-16
   PubMed Web of Science ®Google Scholar
• Habermann T, Weller EA, Morrison V, Rituximab-CHOP versus CHOP alone or with maintenance Rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24(19):3121-7
   PubMed Web of Science ®Google Scholar
• Vellenga E, van Putten WL, van 't Veer MB, Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+NHL: a prospective randomized HOVON trial. Blood 2008;111(2):537-43
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla J, Couban S, Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12. ASH 2012 abstract 745
   Google Scholar
• Gisselbrecht C, Glass B, Mounier N, B-cell lymphoma in the rituximab era. Clin Oncol 2010;28(27):4184-90
   Web of Science ®Google Scholar
• Gisselbrecht C, Schmitz N, Mounier N, Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. JCO 2012;30(36):4462-9
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Smith P, Norton A, British National Lymphoma Investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362(9383):516-22
   PubMed Web of Science ®Google Scholar
• Ardeshna K, Smith P, Qian W, An Intergroup randomised trial of Rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (Grades 1, 2 and 3a). A Preliminary Analysis; ASH abstract presented Dec 2010; https://ash.confex.com/ash/2010/webprogram/Paper27692.html
   Google Scholar
• Marcus R, Imrie K, Belch A, CVP chemotherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphoma. Blood 2005;105(4):1417-23
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Clin Oncol 2008;26(28):4579-86
   Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106(12):3725-32
   PubMed Web of Science ®Google Scholar
• Rummel M, Niederle N, Maschmeyer G, Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. ASCO abstract; 2012
   Google Scholar
• Salles G, Seymour J, Offner F, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a Phase III, randomised controlled trial. Lancet 2011;377(9759):42-51
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz S, Cogliatti S, Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004;103(12):4416-23
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne R, Maintenance Rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized Phase III ECOG1496 study. J Clin Oncol 2009;27(10):1607-14
   PubMed Web of Science ®Google Scholar
• Hornberger J, Chien R, Friedmann M, Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy (abstract). Leuk Lymphoma 2012;53(12):2371-7
   PubMed Web of Science ®Google Scholar
• Available from: http://guidance.nice.org.uk/TA226
   Google Scholar
• Van Oers M, Klasa R, Marcus R, Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized Phase III intergroup trial. Blood 2006;108(10):3295-301
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, The addition of Rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphoma: results of a prospective randomised study of the German low grade lymphoma study group. Blood 2004;104(10):3064-71
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Salles G, Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011;103(23):1799-806
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108(13):4003-8
   PubMed Web of Science ®Google Scholar
• van Oers MH, Van Glabbeke M, Giurgea L, Rituximab maintenance treatment of relapsed/resistant follicular non-hodgkin's lymphoma: long-term outcome of the EORTC 20981 Phase III randomized intergroup study. J Clin Oncol 2010;28(17):2853-8
   PubMed Web of Science ®Google Scholar
• Robak T. Rituximab for chronic lymphocytic Leukemia. Expert Opin Biol Ther 2012;12(4):503-15
   PubMed Web of Science ®Google Scholar
• Available from: https://ash.confex.com/ash/2011/webprogram/Paper40796.html
   Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012;367(6):520-31
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23(9):1984-92
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius J, Trelle S, Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99(9):706-14
   PubMed Web of Science ®Google Scholar
• Zucca E, Conconi A, Laszlo D, Addition of Rituximab to Chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol 2013;31(5):565-72
   PubMed Web of Science ®Google Scholar
• Barnes J, LaCasce A, Feng Y, Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol 2011;22:1859-64
   PubMed Web of Science ®Google Scholar
• Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 2009;10(6):588-96
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lõpez AJ, Link BK, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-33
   PubMed Web of Science ®Google Scholar